GIPERTONIYA VA 2-TIP QANDLI DIABETGA CHALINGAN BEMORLARDA YURAK-QON TOMIR TIZIMI REMODELLASHUVINI DAVOLASHNING ZAMONAVIY YONDASHUVLARI.
Keywords:
arterial gipertenziya, 2-tip qandli diabet,, yurak-qon tomir tizimi,, qayta shakllanish,, empagliflozin,, perindopril.Abstract
Arterial gipertenziya (AG) va 2-tip qandli diabet (QD2) yurak-qon tomir kasalliklarining rivojlanishini keskin kuchaytiruvchi asosiy xavf omillari hisoblanadi. Ayniqsa, ekologik va ijtimoiy-iqtisodiy sharoitlari murakkab bo‘lgan Xorazm viloyati sharoitida ushbu muammo yanada dolzarbdir.
References
1. Williams B., Mancia G., Spiering W., et al. 2023 ESC/ESH Guidelines for the management of arterial hypertension // European Heart Journal. – 2023. – Vol. 44 (19). – P. 1735–1852.
2. American Diabetes Association. Standards of Care in Diabetes — 2024 // Diabetes Care. – 2024. – Vol. 47, Suppl. 1. – P. S1–S188.
3. Whelton P.K., Carey R.M., Aronow W.S., et al. 2022 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults // Journal of the American College of Cardiology. – 2022. – Vol. 79 (20). – P. e101–e199.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes // Lancet. – 1998. – Vol. 352 (9131). – P. 837–853.
5. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // New England Journal of Medicine. – 2008. – Vol. 358 (24). – P. 2560–2572.
6. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus // New England Journal of Medicine. – 2010. – Vol. 362 (17). – P. 1575–1585.
7. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes // New England Journal of Medicine. – 2015. – Vol. 373 (22). – P. 2117–2128.
8. Neal B., Perkovic V., Mahaffey K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes // New England Journal of Medicine. – 2017. – Vol. 377 (7). – P. 644–657.
9. Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes // New England Journal of Medicine. – 2016. – Vol. 375 (4). – P. 311–322.
10. Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND trial) // Lancet. – 2019. – Vol. 394 (10193). – P. 121–130.
11. World Health Organization. Global report on hypertension. – Geneva: WHO, 2023. – 115 p.
12. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. Surunkali kasalliklarning tarqalishi bo‘yicha epidemiologik kuzatuvlar. – Toshkent: SSV nashriyoti, 2022. – 84 b.
13. Глобальная инициатива по хронической обструктивной болезни легких (GOLD). Глобальная стратегия диагностики, лечения и профилактики ХОБЛ: отчет 2023. – Женева: ВОЗ, 2023. – 168 с.
14. Чучалин А.Г. Хроническая обструктивная болезнь легких: современное состояние проблемы // Терапевтический архив. – 2020. – Т. 92, № 8. – С. 4–12.
15. Vogelmeier C.F., Criner G.J., Martinez F.J., et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2023 Report // American Journal of Respiratory and Critical Care Medicine. – 2023. – Vol. 207, No. 10. – P. 1197–1223.
16. European Society of Cardiology (ESC). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice // European Heart Journal. – 2021. – Vol. 42, No. 34. – P. 3227–3337.
17. Barnes P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease // Journal of Allergy and Clinical Immunology. – 2016. – Vol. 138, No. 1. – P. 16–27.
18. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention // Lancet. – 2007. – Vol. 370, No. 9589. – P. 786–796
